Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety Act Expands Withdrawal Authority; Final Decision Rests With Commissioner

This article was originally published in The Pink Sheet Daily

Executive Summary

The proposed FDA Safety Act would enable the Center for Postmarket Drug Evaluation & Research to call for a drug's withdrawal, with final authority retained by the FDA commissioner

You may also be interested in...



FDA Would Lose Direct Access To User Fees Under House Bill

FDA would lose the ability to negotiate with user fee payors on use of the funds under legislation introduced by Rep. Hinchey (D-N.Y.). The bill also would place restrictions on advisory committee members with financial ties to the industry.

FDA Would Lose Direct Access To User Fees Under House Bill

FDA would lose the ability to negotiate with user fee payors on use of the funds under legislation introduced by Rep. Hinchey (D-N.Y.). The bill also would place restrictions on advisory committee members with financial ties to the industry.

FDA Safety Act Proposes Fines For Failure To Comply With Drug Safety Office

Center for Postmarket Drug Evaluation & Research would be able to levy fines starting at $250,000 for failure to complete postmarketing studies on time and for failure to comply with "corrective actions" under the legislation. FDASA would give the independent drug safety office authority over labeling changes and promotional materials.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel